Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Research Article
5 October 2020

The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany

Authors: Sarah Hofmann [email protected], Sebastian Himmler, Dennis Ostwald, Ulrich Dünzinger, Aino Launonen, and Per-Olof ThuressonAuthor Info & Affiliations
Volume 9, Number 14
https://doi.org/10.2217/cer-2020-0131
PDFFormats

Abstract

In this study, we assessed the productivity gains associated with the use of obinutuzumab in combination with chemoimmunotherapy (G-chemo) in first-line treatment among follicular lymphoma patients. Health benefits, measured as an increase in progression-free survival, were translated into productivity gains in both paid and unpaid work using gross value added as productivity measure. From 2017 to 2030, 11,870 overall progression-free years can be gained by utilizing obinutuzumab. These progression-free years correspond to undiscounted productivity gains of about €187.9 million in paid work and about €535.9 million in unpaid work. Our study shows that the benefits of the use of obinutuzumab in the first-line treatment of follicular lymphoma extend beyond clinical advantages.

Lay abstract

Despite effective treatment options, follicular lymphoma is still incurable and is associated with frequent relapses. Patients with hematological cancers are among those most likely to experience work impairment due to their condition. Novel treatments such as an obinutuzumab-based chemotherapy, however, can improve patients’ progression-free survival considerably and enable them to pursue their everyday activities and participate in the labor market. In this study, we quantify how much work productivity can be generated by treating patients with an obinutuzumab-based therapy instead of with the alternative standard therapy. Our results show that, when taking together all expected new follicular lymphoma patients in Germany from 2017 to 2030, the overall productivity that can potentially be generated amounts to €723.8 million, including productivity from both paid work and unpaid work such as housekeeping or childcare.

Supplementary Material

File (suppl_data.zip)

References

Papers of special note have been highlighted as: •• of considerable interest
1.
Robert Koch Institute. Follikuläres non-hodgkin-lymphom (ICD-10 Code C82). Zentrum Für Krebsregisterdaten (2018). http://www.krebsdaten.de/abfrage
Google Scholar
2.
Short PF, Vasey JJ, BeLue R. Work disability associated with cancer survivorship and other chronic conditions. Psychooncology 17(1), 91–97 (2008).
PubMed
Google Scholar
3.
Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS. The effects of chronic medical conditions on work loss and work cutback. J. Occup. Environ. Med. 43(3), 218 (2001).
PubMed
Google Scholar
4.
Munir F, Yarker J, McDermott H. Employment and the common cancers: correlates of work ability during or following cancer treatment. Occup. Med. 59(6), 381–389 (2009).
Google Scholar
5.
Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4), 1417–1423 (2005).
PubMed
Google Scholar
6.
Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol. 26(28), 4579–4586 (2008).
PubMed
Google Scholar
7.
Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12), 3725–3732 (2005).
PubMed
Google Scholar
8.
Guzauskas GF, Masaquel A, Thuresson P-O, Dawson K, Veenstra DL. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. Leuk. Lymphoma 60(7), 1668–1676 (2019).
PubMed
Google Scholar
•• Cost–effectiveness model that forms the basis for our calculations of the health footprint.
9.
Marcus R, Davies A, Ando K et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N. Engl. J. Med. 377(14), 1331–1344 (2017).
PubMed
Google Scholar
•• Main evaluation of the clinical trial that compares obinutuzmab-based chemotherapy to rituximab-based chemotherapy in patients with follicular lymphoma.
10.
Destatis. Allgemeine Sterbetafel 2010/12. Statistisches Bundesamt, Wiesbaden, Germany (2015).
Google Scholar
11.
EMA. European Public Assessment Report (EPAR) for Gazyvaro, Annex I – Summary of Product Characteristics. (2018). https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro
Google Scholar
12.
Roche Pharma AG. Dossier zur Nutzenbewertung gemäß § 35a SGB V – Obinutuzumab (Gazyvaro) – Modul 3 A. (2017). https://www.g-ba.de/downloads/92-975-2137/2017-09-21_Modul1_Obinutuzumab.pdf
Google Scholar
13.
Himmler S, Müller M, Ostwald D, Seddik A, Basic E, Hradetzky E. Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study. Expert Rev. Pharmacoecon. Outcomes Res. 19(2), 223–230 (2019).
PubMed
Google Scholar
14.
Pettengell R, Donatti C, Hoskin P et al. The impact of follicular lymphoma on health-related quality of life. Ann. Oncol. 19(3), 570–576 (2008).
PubMed
Google Scholar
15.
Miranda V. Cooking, caring and volunteering: unpaid work around the world. OECD Soc. Employ. Migr. Work. Pap. No. 116 (2011) (Online).
Crossref
Google Scholar
16.
Krol M, Brouwer W. Unpaid work in health economic evaluations. Soc. Sci. Med. 144, 127–137 (2015).
PubMed
Google Scholar
17.
Destatis. Statistisches Jahrbuch 2016 – Kapitel 13 – Arbeitsmarkt. Statistisches Bundesamt, Wiesbaden, Germany (2016).
Google Scholar
18.
Destatis. Die Generation 65+ in Deutschland. Statistisches Bundesamt, Wiesbaden, Germany (2015).
Google Scholar
19.
Spelten ER, Verbeek JHAM, Uitterhoeve ALJ et al. Cancer, fatigue and the return of patients to work – a prospective cohort study. Eur. J. Cancer 39(11), 1562–1567 (2003).
PubMed
Google Scholar
20.
Horsboel TA, Nielsen CV, Nielsen B, Jensen C, Andersen NT, de Thurah A. Type of hematological malignancy is crucial for the return to work prognosis: a register-based cohort study. J. Cancer Surviv. 7(4), 614–623 (2013).
PubMed
Google Scholar
21.
Short PF, Vasey JJ, Tunceli K. Employment pathways in a large cohort of adult cancer survivors. Cancer 103(6), 1292–1301 (2005).
PubMed
Google Scholar
22.
Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample. J. Natl Cancer Inst. 96(17), 1322–1330 (2004).
PubMed
Google Scholar
23.
Cheung MC, Imrie KR, Friedlich J, Buckstein R, Lathia N, Mittmann N. The impact of follicular (FL) and other indolent non-Hodgkin's lymphomas (NHL) on work productivity – a preliminary analysis. Psychooncology 18(5), 554–559 (2009).
PubMed
Google Scholar
24.
Andresen S, Brandt J, Dietrich S, Memmer M-L, Ho AD, Witzens-Harig M. The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma. Leuk. Lymphoma 53(3), 386–393 (2012).
PubMed
Google Scholar
25.
Destatis. Volkswirtschaftliche Gesamtrechnung: Inlandsproduktberechnung Detaillierte Jahresergebnisse 2015. Chapter: Fachserie 18, Reihe 1.4. Statistisches Bundesamt, Wiesbaden Germany (2016).
Google Scholar
26.
Leontief WW. Quantitative input and output relations in the economic systems of the United States. Rev. Econ. Stat. 18(3), 105 (1936).
Google Scholar
27.
Miller RE, Blair PD. Input–Output Analysis: Foundations and Extensions (2nd Edition). Cambridge University Press, Cambridge, UK (2012). http://ebooks.cambridge.org/ref/id/CBO9780511626982
Google Scholar
28.
Destatis. Zeitverwendungserhebung - Aktivitäten in Stunden und Minuten für ausgewählte Personengruppen - 2012/2013. Statistisches Bundesamt, Wiesbaden, Germany (2015).
Google Scholar
29.
Reid MG. Economics of Household Production. J. Wiley & Sons, NY, USA (1934). http://archive.org/details/economicsofhouse00reid
Google Scholar
•• Very fundamental work on valuing household production that provides the basis for our approach to monetarize unpaid work.
30.
Hofmann S. Einfluss nicht-marktlicher Tätigkeiten auf den materiellen Wohlstand und die Einkommensverteilung in Deutschland. Peter Lang International Academic Publishers, Bern, Switzerland (2015). https://www.econstor.eu/handle/10419/178485
Google Scholar
31.
van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GAM, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc. Sci. Med. 62(4), 835–845 (2006).
PubMed
Google Scholar
32.
Guzauskas GF, Masaquel A, Reyes C, Wilhelm K, Krivasi T, Veenstra DL. What is the cost–effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US? Blood 128(22), 3605–3605 (2016).
Google Scholar
33.
Haukaas FS, Ohna A, Krivasi T. Cost–effectiveness of obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance versus bendamustine alone in treatment of patients with rituximab-refractory follicular lymphoma in Norway. Appl. Health Econ. Health Policy 16(4), 569–577 (2018).
PubMed
Google Scholar
34.
Foster T, Miller JD, Boye ME, Russell MW. Economic burden of follicular non-hodgkin’s lymphoma. Pharmacoeconomics 27(8), 657–679 (2009).
PubMed
Google Scholar
35.
Krol M, Brouwer W. Unpaid work in health economic evaluations. Soc. Sci. Med. 144, 127–137 (2015).
PubMed
Google Scholar
•• Comprehensive review of how unpaid work is currently included in health economic evaluations. The review shows that despite its importance, unpaid work is only rarely included. It underlines the importance of studies like the present one.
36.
Mazanec SR, Daly BJ, Douglas SL, Lipson AR. Work productivity and health of informal caregivers of persons with advanced cancer. Res. Nurs. Health 34(6), 483–495 (2011).
PubMed
Google Scholar
38.
Krol M, Papenburg J, Tan SS, Brouwer W, Hakkaart L. A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. Eur. J. Health Econ. 17(4), 391–402 (2016).
PubMed
Google Scholar
|